AIM ImmunoTech Sets Date for Q3 2023 Financial Results and Conference Call

OCALA, Fla. — AIM ImmunoTech Inc. AIM, a leader in immunological research with a focus on cancer treatment, immune disorders, and viral diseases, has announced a pivotal event for investors and interested parties. The company will host a conference call and webcast on November 15, 2023, to discuss operational and financial outcomes for the third quarter of the year 2023.

Conference Call Details

Thomas K. Equels, the Chief Executive Officer, and Christopher McAleer, PhD, the Scientific Officer, will lead the conference call scheduled for 8:30 AM ET. Those wishing to participate may dial in using the numbers (877) 407-9219 for domestic calls or (201) 689-8852 for international access, referencing the AIM ImmunoTech Conference Call. Additionally, a webcast will be available, providing a direct visual feed for participants, which can be found on the Events page of the Investors section at aimimmuno.com. This webcast will also be archived on the company's website for 90 days post-event.

About AIM ImmunoTech Inc.

With a reputation for excellence in the field of immune-oncology, AIM ImmunoTech AIM is dedicated to the development of medical advancements like their flagship investigational drug, Ampligen^® (rintatolimod). This drug is a double-stranded RNA (dsRNA) with promising activity as a TLR3 agonist immuno-modulator. It’s currently being tested in clinical trials across various significant cancers, viral diseases including COVID-19, and immune system disorders.

Linking Investors With Information

The company urges investors and the general public to visit their website aimimmuno.com for more insights into their operations and achievements. AIM ImmunoTech maintains an active presence on social media platforms Twitter, LinkedIn, and Facebook, where it shares updates and connects with the community.

The Broader Picture for Investors

Within the investment landscape, AIM's strides in the biotech sphere are noted with interest, as are movements in tech giants such as Meta Platforms, Inc. META. Based in Menlo Park, California, Meta Platforms delivers a suite of connection-facilitating products used worldwide—spanning from mobile and PC software to cutting-edge virtual reality and wearable technologies.

AIM, META, Investment